10/03/23 7:00 AMNasdaq : RDHL low floatRedHill and U.S. Army Announce Opaganib's Ebola Virus Disease Survival Benefit in U.S. Army-Funded In-Vivo StudyRedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that novel, twice daily, oral opaganib, delivered a statistically significant increase in...RHEA-AIneutral
09/22/23 4:15 PMNasdaq : RDHL low floatRedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price DeficiencyRedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that on September 19, 2023, it received a letter from the Listings Qualifications Department of The Nasdaq Stock Market LLC indicating that, for the thirty consecutive business days from August 7, 2023, to September 18,...RHEA-AIneutral
09/18/23 7:00 AMNasdaq : RDHL low floatRedHill Announces FDA sNDA Approval for Talicia®RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced the U.S. Food and Drug...RHEA-AIneutral
09/05/23 7:00 AMNasdaq : RDHL low floatRedHill Announces New USPTO Notice of Patent Allowance for Opaganib and EU Patent Grant for RHB-102 (BEKINDA®)RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that the U.S. Patent and Trademark Office had issued a Notice of Allowance for a new opaganib patent covering sphingosine kinase 2 inhibition treatment for Ebola virus disease, supporting opaganib pro tection until...RHEA-AIneutral
08/17/23 7:00 AMNasdaq : RDHL earningslow floatRedHill Biopharma Provides H1/23 Financial Results and Operational HighlightsRHB-107 included in the U.S. Department of Defense-supported ACESO PROTECT multinational platform trial for early COVID-19 outpatient treatment; The 300- patient Phase 2 study received FDA clearance and is estimated to be completed by the end of 2024. Opaganib awarded a further $1.7 million in U.S. government medical countermeasure development funding–...RHEA-AIneutral
08/01/23 7:00 AMNasdaq : RDHL low floatRedHill Biopharma Announces Talicia Approved in the United Arab Emirates and First Commercial Order Outside the U.S.RedHill's partner, Gaelan Medical, part of the Ghassan Aboud Group, receives marketing approval from the United Arab Emirates Ministry of Health for Talicia. Talicia, a novel rifabutin-containing all-in-one oral capsule specifically designed to treat H. pylori, is the leading branded first-line therapy prescribed by U.S. gastroenterologists for...RHEA-AIneutral
07/31/23 7:00 AMNasdaq : RDHL covid-19low floatRedHill's RHB-107 Included in U.S. Government-Supported COVID-19 Platform Trial and Cleared for Initiation by FDARHB-107 accepted for inclusion in ACESO's PROTECT adaptive platform trial for early COVID-19 outpatient treatment to be conducted in the U.S., Thailand, Ivory Coast and South Africa. The substantial 300- patient Phase 2 study, predominantly funded by the U.S. Government Department of Defense's Joint Program Executive Office for Chemical, Biological,...RHEA-AIneutral
07/25/23 3:58 PMNasdaq : RDHL offeringlow floatRedHill Biopharma Announces Closing of $3.8 Million Registered Direct Offering and Warrant ExerciseRedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that it has closed its previously announced registered direct offering for the purchase and sale of 1,301,923 of the Company's American Depositary Shares, each ADS representing four hundred ordinary shares, at a...RHEA-AIneutral
07/21/23 9:33 AMNasdaq : RDHL offeringlow floatRedHill Biopharma Announces Registered Direct Offering and Warrant Exercise for $3.8 Million Gross ProceedsRedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that it has entered into definitive agreements with institutional investors for the purchase and sale of 1,301,923 of the Company's American Depositary Shares, each ADS representing four hundred ordinary shares, at a...RHEA-AIneutral
07/21/23 7:00 AMNasdaq : RDHL low floatRedHill Announces Additional U.S. Government Funding for Opaganib Nuclear Countermeasure DevelopmentOpaganib awarded a further $1.7 million in U.S. Government funding for development as a medical countermeasure for gastrointestinal acute radiation syndrome. The Small Business Innovation Research grant, given to RedHill's development partner, Apogee, is in addition and complementary to the multimillion dollar-valued U.S. Government Radiation and...RHEA-AIneutral